A phase 2b Diabetic Kidney Disease study

Study identifier:D9183C00001

ClinicalTrials.gov identifier:NCT04170543

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease

Medical condition

Diabetic Kidney Disease

Phase

Phase 2

Healthy volunteers

No

Study drug

MEDI3506, Placebo, Dapagliflozin

Sex

All

Actual Enrollment

609

Study type

Interventional

Age

18 Years - 101 Years

Date

Study Start Date: 18 Nov 2019
Primary Completion Date: 16 May 2023
Study Completion Date: 16 May 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria